Annual Drug Patent Expirations for FARXIGA
Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from three suppliers. There are eighteen patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for FARXIGA.
This drug has three hundred and twenty-two patent family members in forty-six countries.
The generic ingredient in FARXIGA is dapagliflozin. Three suppliers are listed for this compound. Additional details are available on the dapagliflozin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
